Weekly semaglutide injection led to greater average weight loss than daily liraglutide injection in a direct 68-week study: 15.8% versus 6.4%. The study compared specific doses in adults with obesity or qualifying overweight who did not have diabetes. If you already take Saxenda, there is a second, more immediate decision to make. Novo Nordisk plans its last U.S. shipments of the brand to wholesalers in late January 2027, so ask about your next fill and a backup plan while you still have medicine. STEP 8 randomized trial · Novo Nordisk’s Saxenda notice
What did the direct trial find about weight loss?
STEP 8 enrolled 338 adults, including participants assigned to placebo. The adult participants had obesity or overweight with a weight-related condition and did not have diabetes. The two active treatment groups knew which drug they received. Both had diet and activity counseling.
| At week 68 | Semaglutide injection | Liraglutide injection |
|---|---|---|
| Study target dose | 2.4 mg once a week | 3 mg once a day |
| Average weight loss | 15.8% | 6.4% |
| Lost at least 15% of starting weight | 55.6% | 12.0% |
The threshold row puts the average in perspective. Even with the larger average for semaglutide, many people in its group lost less than 15%. The study also handled trouble reaching the target dose differently. People who couldn’t tolerate 2.4 mg semaglutide could stay at 1.7 mg. People unable to tolerate 3 mg liraglutide discontinued, with the option to restart dose escalation. That difference belongs alongside the weight findings when you consider how much of the treatment protocol you could follow. STEP 8 methods and results
Does this tell you how Wegovy tablets or diabetes products compare?
The study tells you about a weekly semaglutide injection and a daily liraglutide injection at the doses above. Saxenda is a daily liraglutide injection for long-term weight management. Wegovy has weekly injectable and daily tablet forms for weight management, with product-specific labeling. STEP 8 did not test the tablet or the 7.2 mg injection option for adults. Victoza and Ozempic are examples of products used for type 2 diabetes, and the STEP 8 participants did not have diabetes. If blood sugar is your priority, ask for evidence that matches the specific diabetes prescription. Saxenda label · Wegovy label · U.S. GLP-1 medications list
How would a daily or weekly injection fit into your life?
A daily Saxenda injection gives you seven injection days in a week. It may be easy to remember beside a task you do every day. With weekly injectable Wegovy, set a reminder for the same day each week. If the day you normally take your medicine overlaps with a split shift or regular travel, check what using and storing the actual pen would involve. Ask the pharmacist to demonstrate the device you would receive and explain what to do if you miss a dose or have a longer interruption. These instructions belong to the product on your prescription. Saxenda label, sections 2 and 16 · Wegovy label, sections 2 and 16
Frequency can help you decide what you can keep doing. How often you inject is a poor shortcut to guessing how nauseated or hungry you might feel. If previous symptoms interrupted meals, drinking or work, describe them to the prescriber. The GLP-1 tolerability comparison explains what the trial’s symptom and stopping rates measure.
When should you review an existing Saxenda prescription?
For adults, the Saxenda label calls for reviewing weight change 16 weeks after starting treatment. The label says to discontinue if you’ve lost less than 4% of starting weight, or if you can’t tolerate the daily 3 mg dose. Ask the prescriber to put those checkpoints into your plan. They are adult Saxenda instructions, with separate criteria for pediatric patients and different directions for Wegovy. Saxenda prescribing information, section 2.2
If Saxenda is helping and you can use it comfortably, ask the pharmacy when it expects to fill your exact prescription. Late January is the manufacturer’s planned last shipment to wholesalers. Your pharmacy’s timeline may differ. If an alternative is needed, have the treatment team identify the exact product and approved purpose, check your coverage and give you a plan for when to make the change. A liraglutide pen can be labeled for a different purpose, and an injectable semaglutide dose uses a different schedule. NovoCare Saxenda availability notice

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



